Novavax reported earnings of -$ 0.19 per NVAX share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.35 |
| Earnings Per Share (Surprise) | -$ 0.19 (+$ 0.1559) |
| Last Year's EPS | $ 0.6025 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Novavax beat analysts’ expectations 42 times and fell short of expectations 50 time(s). Novavax reported earnings per share of -$ 0.19 in the last report surpassing an estimated EPS of -$ 0.35 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.35 | -$ 0.19 | -$ 1.25 | |
| Aug 6, 2026 | -$ 0.38 | -$ 0.32 | $ 0.62 | |
| May 6, 2026 | -$ 0.25 | -$ 0.06 | $ 2.93 | |
| Feb 26, 2026 | -$ 0.66 | $ 0.11 | -$ 0.51 | |
| Nov 6, 2025 | -$ 1.08 | -$ 1.25 | -$ 0.76 | |
| Aug 6, 2025 | -$ 0.07 | $ 0.62 | $ 0.99 | |
| May 8, 2025 | $ 0.71 | $ 2.93 | -$ 1.05 | |
| Feb 27, 2025 | -$ 0.75 | -$ 0.51 | -$ 1.44 | |
| Nov 12, 2024 | -$ 0.87 | -$ 0.76 | -$ 1.26 | |
| Aug 8, 2024 | $ 1.64 | $ 0.99 | $ 0.58 | |
| May 10, 2024 | -$ 1.04 | -$ 1.05 | -$ 3.41 | |
| Feb 28, 2024 | -$ 0.49 | -$ 1.44 | -$ 2.28 | |
| Nov 9, 2023 | -$ 1.82 | -$ 1.26 | -$ 2.15 | |
| Aug 8, 2023 | -$ 1.39 | $ 0.58 | -$ 6.53 | |
| May 9, 2023 | -$ 3.38 | -$ 3.41 | $ 2.56 | |
| Feb 28, 2023 | -$ 0.92 | -$ 2.28 | -$ 11.18 | |
| Nov 8, 2022 | $ 2.21 | -$ 2.15 | -$ 4.31 | |
| Aug 8, 2022 | $ 5.51 | -$ 6.53 | -$ 4.75 | |
| May 9, 2022 | $ 2.69 | $ 2.56 | -$ 3.05 | |
| Feb 28, 2022 | -$ 1.43 | -$ 11.18 | -$ 2.70 |
Novavax’s stock was trading at $ 10.65 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, NVAX’s price increased to $ 10.78 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.19 | $ 10.65 | $ 10.78 | |
| Aug 6, 2026 | -$ 0.32 | $ 7.70 | $ 7.95 | |
| May 6, 2026 | -$ 0.06 | $ 8.10 | $ 9.23 | |
| Feb 26, 2026 | $ 0.11 | $ 9.53 | $ 10.14 | |
| Nov 6, 2025 | -$ 1.25 | $ 7.69 | $ 7.44 | |
| Aug 6, 2025 | $ 0.62 | $ 6.73 | $ 8.78 | |
| May 8, 2025 | $ 2.93 | $ 5.95 | $ 5.98 | |
| Feb 27, 2025 | -$ 0.51 | $ 7.32 | $ 8.33 | |
| Nov 12, 2024 | -$ 0.76 | $ 9.01 | $ 7.77 | |
| Aug 8, 2024 | $ 0.99 | $ 10.71 | $ 11.60 | |
| May 10, 2024 | -$ 1.05 | $ 4.47 | $ 13.11 | |
| Feb 28, 2024 | -$ 1.44 | $ 6.02 | $ 4.94 | |
| Nov 9, 2023 | -$ 1.26 | $ 6.80 | $ 6.24 | |
| Aug 8, 2023 | $ 0.58 | $ 7.52 | $ 7.12 | |
| May 9, 2023 | -$ 3.41 | $ 7.45 | $ 8.99 | |
| Feb 28, 2023 | -$ 2.28 | $ 8.67 | $ 6.86 | |
| Nov 8, 2022 | -$ 2.15 | $ 19.43 | $ 18.63 | |
| Aug 8, 2022 | -$ 6.53 | $ 60.27 | $ 40.28 | |
| May 9, 2022 | $ 2.56 | $ 57.30 | $ 53.86 | |
| Feb 28, 2022 | -$ 11.18 | $ 81.63 | $ 83.74 |
Novavax released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Novavax beat analysts’ expectations during the last earnings period by
